ABSTRACT Purpose. We have previously reported that older patients with clinical stage I and II primary cutaneous. Melanoma had lower survival rates compared to younger patients. We postulated that the incidence of nodal metastasis would therefore be higher among older melanoma patients. Methods. The expanded American Joint Committee on Cancer melanoma staging database contains a cohort of 7,756 melanoma patients who presented without clinical evidence of regional lymph node or distant metastasis and who underwent a sentinel node biopsy procedure as a component of their staging assessment.
Results. Although older patients had primary melanoma features associated with more aggressive biology, we paradoxically observed a significant decrease in the incidence of sentinel node metastasis as patient age increased. Overall, the highest incidence of sentinel node metastasis was 25.8 % in patients under 20 years of age, compared to 15.5 % in patients 80 years and older (p \ 0.001). In contrast, 5-year mortality rates for clinical stage II patients ranged from a low of 20 % for those 20-40 years of age up to 38 % for those over 70 years of age. Patient age was an independent predictor of sentinel node metastasis in a multifactorial analysis (p \ 0.001). Conclusions. Patients with clinical stage I and II melanoma under 20 years of age had a higher incidence of sentinel lymph node metastasis but, paradoxically, a more favorable survival outcome compared to all other age groups. In contrast, patients [70 years had the most aggressive primary melanoma features and a higher mortality rate compared to all other age groups but a lower incidence of sentinel lymph node metastasis.
We have previously reported that patient age is a highly significant and independent predictor of survival outcome using the American Joint Committee on Cancer (AJCC) melanoma staging database, even after accounting for the pathological features of the primary melanoma as well as clinical features, including the anatomic site of disease and the gender of the patient. [1] [2] [3] Recently, we reported that with increasing age by decade, multiple characteristics of primary melanoma became more advanced: tumors were thicker, exhibited higher mitotic rates, and were more likely to be ulcerated. For patients with localized melanoma (stage I/II), the mean thickness at presentation for patients over 70 years of age was almost twice that of patients who were 40-60 years of age. 3 From this observation, we postulated that older patients with clinically localized melanoma might have a higher incidence of occult nodal metastases as one explanation of why they exhibited a lower survival rate, and conversely that younger patients should have a corresponding lower incidence of occult nodal metastases.
METHODS
The AJCC melanoma staging database was originally created in 1999 as a result of an international collaboration that combined prospective melanoma databases from 18 major cancer centers and a clinical trial cooperative group. 1, 4 Using a version that was updated in 2008, an evidence-based approach was used to revise the AJCC melanoma staging system; these revisions were included in the 7th edition of the AJCC melanoma staging manual published in 2009. 5 This comprehensive database included 11,088 stage I and II patients with complete data, including mitotic rate for multivariate analysis of patient age sorted by decade, along with other key clinicopathological prognostic factors. Among these 11,088 patients, a cohort of 7,756 melanoma patients presented without clinical evidence of regional lymph node or distant metastases and underwent a lymphatic mapping and sentinel node biopsy procedure as a component of their staging assessment. Details of this AJCC melanoma staging database have been published previously. 1, 3, 5 Characteristics of the 28,047 patients partitioned according to age groups have recently been published. 3 Survival times were calculated from the date of initial melanoma diagnosis and censored for patients who were alive at last follow-up or who died without evidence of melanoma. Standard statistical methods were used; melanoma-specific survival curves were generated by the Kaplan-Meier product-limit method and compared by the log rank test, and multivariate analyses were based on logistics regression analysis to assess the incidence of sentinel node metastasis. 1, 6 For the Cox multivariate analyses, the relative importance of the prognostic factors was determined according to v 2 values (with associated degrees of freedom [df] and p values). 6 
RESULTS
Among the 7,756 patients in the present study, all of whom underwent sentinel node biopsy, 1,507 (19.4 %) had at least one sentinel lymph node (SLN) metastasis (Table 1) .
There was a significant decrease in the incidence of sentinel node metastasis as patient age increased (Fig. 1) . Overall, the highest incidence of SLN metastasis was 25.8 % in patients under 20 years of age. In contrast, only 15.5 % had SLN metastasis among patients 80 years and older (p \ 0.001), despite the observation that these older patients had primary tumor features (e.g., thicker tumors, higher mitotic rate, ulcers) associated with more aggressive biology (data not shown). Among patients with clinical stage I melanoma who underwent a SLN biopsy, the incidence of sentinel node metastases decreased from 14.8 % for patients aged 20-30 years to 3.6 % for those 80 years of age or older (Fig. 1a) . The incidence decreased from 35.6 % for those 20 years and under who had clinical stage II melanoma to 20.2 % for those 80 years of age or older (Fig. 1a) . When the incidence of sentinel node metastasis was stratified by clinical primary tumor substage and age among all patients with primary melanoma who underwent sentinel node biopsy, the incidence of sentinel node metastasis for patients with clinical stage IA melanoma was \10 % for all age groups; for clinical stage 1B melanoma, the incidence decreased from 20 % for those under 20 years of age to 5 % for those 80 years of age or older (data not shown). Among patients with clinical stage II melanoma, a significant decrease in SLN metastasis incidence could be seen across all decades of age (Fig. 1b) . Among patients with T3/T4 melanomas who underwent a SLN biopsy, the same trends were observed and were particularly significant for patients with thick, ulcerated (T4b) melanomas (Fig. 1c) . Interestingly, an inverse association was observed with increasing age between the incidence of sentinel node metastasis with and melanoma mortality rate for clinical stage II patients (Fig. 1d) . The highest incidence of sentinel node metastasis was identified in patients under 20 years of age, yet their 5-year mortality was only 10 %. In contrast, patients aged 20-50 had a 26 % incidence of sentinel node metastasis that declined to 24 % for those 70 years of age or older, while 5-year mortality rates ranged from a low of 20 % for those 20-40 years of age up to 38 % for those over 70 years of age and reached 45 % for those age 80 years or older (Fig. 1d ). Patient age was a statistically significant independent predictor of sentinel node metastasis in both the univariate analysis and multivariable analysis. Specifically, the incidence of sentinel node metastasis decreased with increasing patient age by univariate analysis (p = 0.074) ( Table 1) ; by multivariate analysis, patient age was also an independent predictor of sentinel node metastasis ( Table 2 ). The most significant predictors of SLN metastasis (p \ 0.0001 for each) were the following: increasing tumor thickness (v 2 = 223), presence of lymphovascular invasion (v 2 = 123), younger patient age (v 2 = 49), trunk or lower extremity location (v 2 = 48), increasing Clark level of invasion (v 2 = 28), and tumor ulceration (v 2 = 25).
DISCUSSION
In this AJCC analysis of 7,756 stage I and II primary cutaneous melanoma patients who underwent sentinel node biopsy, we observed an inverse relationship between melanoma mortality. In addition, there was an inverse relationship between age and the incidence of sentinel node metastasis when sorted by decade of age. Thus, patients with clinical stage I and II melanoma under 20 years of age had more adverse features in their primary melanoma, a higher incidence of SLN metastasis, and, paradoxically, a more favorable survival when compared to all other age groups. 3 In contrast, patients aged [70 years had the most adverse primary melanoma features and higher mortality rates compared to all other age groups, but paradoxically had a lower incidence of SLN metastasis.
Perhaps the most interesting finding from our study, and supported by previous studies, is the lower incidence of SLN metastasis despite higher mortality rate among older melanoma patients, and conversely, the higher incidence of sentinel node metastasis despite a lower mortality rate among younger melanoma patients. These data exemplify the heterogeneity of melanoma and the diversity of outcomes that must be accounted for both by clinicians and investigators. The biological implications of this paradox are provocative and support an interesting series of hypotheses to be tested in future studies. Primary melanomas in the very young and in the elderly population may have differing biological features, alternative routes of metastasis, and/or divergent host responses to the metastatic process, especially with regard to immune competence; these differences may contribute to the observed differences in mortality rates. It is also possible that there could be a bias to the more liberal use of SLN biopsy in young patients and, conversely, its more conservative use in older patients. An inverse relationship between sentinel node metastasis rate and patient age was first described in 2004 by Chao et al. and by Sondak et al. 7, 8 Others have reported that age is an independent factor in predicting the risk of SLN metastasis. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In the Sunbelt Melanoma Trial involving over 3,000 patients who had a sentinel node biopsy, the incidence of nodal metastasis for those B30 years was 23 % compared to only 12 % among patients aged 61-70 years (p = 0.018). 15 The inverse relationships between older patients (higher mortality and lower incidence of sentinel node metastasis) and younger patients (lower mortality rates and higher incidence of sentinel node metastasis) compared to adult patients aged 20-60 years suggests that unaccounted features of the host and the disease, such as levels of immune competence, age-related changes in lymphatic function, or other biological features of the primary melanoma, such as hematogenous route of metastases or altered lymphangiogenesis, might be operative in these patients at extremes of age. 26, 27 This may be related to a previously reported age-related decline in the ability of melanoma cells to move radiocolloid from the peritumoral dermis to the sentinel node and retain it in that location. 26 It is known that different types of primary melanoma (e.g., desmoplastic, lentigo malignant, spitzoid) with different prognosis are distributed unequally across age groups; many with more favorable outcome appear to be more prominent in younger patients. One limitation of our AJCC database is that we did not have systematic reporting or central pathologic review of melanoma subtype in order to adjust for this variable in our analysis. In addition, frailty among the older population as measured by sarcopenia could adversely influence survival outcome and increase complication rates, especially among elderly melanoma patients. 28, 29 These data might also explain why older patients were less likely to have a survival benefit from lymphadenectomy compared to those \60 years of age. 30 Older patients have a greater preponderance of acral lentiginous melanomas as well as head and neck melanomas, including desmoplastic melanomas, that are associated with a lower incidence of nodal metastasis. [31] [32] [33] [34] [35] In addition, overlapping anatomic structures make it difficult to localize head and neck SLNs on routine lymphoscintigraphy. The recent use of single-photon emission tomography/computed tomography has substantially increased the accuracy of identifying the sentinel node among head and neck melanoma patients whose disease heretofore may have been understaged. 36 Overall, these observations may help inform evolving indications for performing a sentinel node biopsy to maximize staging in younger patients, and to potentially offer this procedure less frequently in older patients who might be spared the extra morbidity of the procedure, especially in the setting of concomitant risk factors and/or comorbidities. 37 There is also a great diversity of melanoma presentations among the very young, as well as a more favorable survival outcome despite a higher incidence of nodal metastases. 32, [37] [38] [39] One explanation is that children or teenagers may have an atypical spitzoid melanocytic tumor or a melanocytic tumor of unknown malignant potential with sentinel node metastasis; both entities are known to have a more favorable prognosis even in stage III melanoma. 11, [40] [41] [42] [43] [44] [45] Another melanoma presentation among teenagers and young adults with an increased incidence of nodal metastasis and a low potential for metastasis growing at distant sites is the ''animal-type melanoma''. 46 These results raise and reiterate some interesting and important hypotheses and emphasize the importance of patient age as a component of melanoma staging and in the design and interpretation of clinical trials for patients with localized disease or with regional node metastases. Just as the genetic profile of acral lentiginous melanomas is distinctly different from melanoma arising in chronic sundamaged skin, so too might melanomas arising in the very young and the very old have a different cause and natural history from those arising in adults aged 20-60 years. 47 These data will, we hope, stimulate a systematic inquiry to examine this possibility. Given the disproportionate rise in incidence among the very young and the disproportionate rise in mortality among older patients with melanoma, these issues are important to address so we can better treat our patients. 48, 49 Further research is also needed to determine if the genetic profile and causative associations are similar or distinct from those of young and middle-aged melanoma patients where ultraviolet radiation is thought to be a primary causative agent.
